PharmaCyte Biotech, Inc. Company profile
About Pharmacyte Biotech Inc
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Cell-in-a-Box technology is used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). The Company's lead product candidate, CypCaps is in Phase II of the clinical trials in LAPC. It also focused on developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The Company is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant, such as cannabinoids.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Pharmacyte Biotech Inc revenues was not reported. Net loss increased 9% to $2.8M. Higher net loss reflects General and administrative increase from $291K to $836K (expense), Legal and professional increase of 85% to $601K (expense), Director fees increase of 1% to $209K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.88 to -$0.74.
Equity composition
Common Stock $0.0001 Par, 03/11, 500M auth., 353,387,581 issd. Insiders own 9.09%. 12/03, 3 for 1 forward stock split. 03/09, Name changed from eFoodSafety.com Inc. Preferred Stock $.0001 Par, 10M auth., 5K issd.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)